The Illumina and Amgen-backed genetic sequencing system developer raised $38.5m while its shareholders sold another $106m in shares.
Oxford Nanopore, a UK-based genetic sequencing technology provider backed by genomics technology producer Illumina and pharmaceutical company Amgen, has attracted £29.3m ($38.5m) in funding from undisclosed new and existing investors.
In addition to the primary funding, the company’s shareholders divested approximately $106m of shares, $28.9m being sold by commercialisation firm IP Group which now owns a 16.4% stake.
The secondary transaction also included shares divested by defunct investment firm Woodford Investment Management and its Woodford Patient Capital Trust, now under…
